In our study, we proposed the following drug resistance model: during paclitaxel therapy for breast cancer, paclitaxel can active ERα expression and then ERα can transcriptionally regulate the CD44 gene, which is responsible for resistance to chemotherapy agents. This evidence concerns the gene ESR1 and breast cancer.